Edition:
India

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

13.32USD
22 Nov 2017
Change (% chg)

$-0.26 (-1.91%)
Prev Close
$13.58
Open
$13.57
Day's High
$13.75
Day's Low
$13.32
Volume
31,256
Avg. Vol
--
52-wk High
$14.90
52-wk Low
$13.25

Latest Key Developments (Source: Significant Developments)

Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc
Wednesday, 22 Nov 2017 

Nov 21 (Reuters) - Apellis Pharmaceuticals Inc :Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc ‍​as of November 13 - SEC filing.  Full Article

Apellis Pharmaceuticals announces closing of its IPO
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Apellis Pharmaceuticals Inc ::Apellis pharmaceuticals announces closing of its initial public offering.  Full Article

Apellis Pharma shares debut about 3.6 pct above IPO price
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - :Apellis Pharmaceuticals Inc shares open at $14.50 in debut on the NASDAQ versus IPO price of $14 per share‍​.  Full Article

Apellis prices IPO of 10.7 mln common shares at $14/shr
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Apellis Pharmaceuticals Inc :Apellis Pharmaceuticals announces pricing of initial public offering.Says initial public offering of 10.7 million common shares priced at $14.00 per share.  Full Article

Apellis Pharmaceuticals sees IPO of 10.71 mln shares‍​ of common stock
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Apellis Pharmaceuticals Inc :Apellis Pharmaceuticals Inc sees IPO of 10.71 million shares‍​ of common stock to be priced between $13.00 and $15.00 per share - sec filing.  Full Article

Apellis Pharma adds Evercore ISI as IPO underwriter
Saturday, 21 Oct 2017 

Oct 20 (Reuters) - Apellis Pharmaceuticals Inc :Apellis Pharmaceuticals Inc says it adds Evercore ISI to underwriters to the IPO - SEC filing‍​.  Full Article

BRIEF-Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc

* Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc ‍​as of November 13 - SEC filing Source text (http://bit.ly/2jcJaxu) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

No consensus analysis data available.